Analysis of Response and Progression Patterns of Tyrosine Kinase Inhibitors in Recurrent or Metastatic Adenoid Cystic Carcinoma: A Post Hoc Analysis of Two KCSG Phase II Trials
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose In this study, we evaluated 66 patients diagnosed with adenoid cystic carcinoma (ACC) enrolled in two Korean Cancer Study Group trials to investigate the response and progression patterns in recurrent and/or metastatic ACC treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs). Materials and Methods We evaluated 66 patients diagnosed with ACC who were enrolled in the Korean Cancer Study Group trials. The tumor measurements, clinical data, treatment outcomes, and progression patterns of therapy were analyzed. Results In the 66 patients (53 receiving axitinib and 13 receiving nintedanib), the disease control rate was 61%, and three patients achieved partial response. The median follow-up, median progression-free survival (PFS), overall survival, and 6-month PFS rate were 27.6%, 12.4%, and 18.1% months and 62.1%, respectively. Among 42 patients who experienced progression, 27 (64.3%) showed target lesion progression. Bone metastasis was an independent poor prognostic factor. Conclusion Overall, most patients demonstrated stable disease with prolonged PFS; however, prominent target lesion progression occurred in some patients. Thus, PFS may capture VEGFR-TKI efficacy better than the objective response rate.
Abstract
Purpose In this study, we evaluated 66 patients diagnosed with adenoid cystic carcinoma (ACC) enrolled in two Korean Cancer Study Group trials to investigate the response and progression patterns in recurrent and/or metastatic ACC treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs). Materials and Methods We evaluated 66 patients diagnosed with ACC who were enrolled in the Korean Cancer Study Group trials. The tumor measurements, clinical data, treatment outcomes, and progression patterns of therapy were analyzed. Results In the 66 patients (53 receiving axitinib and 13 receiving nintedanib), the disease control rate was 61%, and three patients achieved partial response. The median follow-up, median progression-free survival (PFS), overall survival, and 6-month PFS rate were 27.6%, 12.4%, and 18.1% months and 62.1%, respectively. Among 42 patients who experienced progression, 27 (64.3%) showed target lesion progression. Bone metastasis was an independent poor prognostic factor. Conclusion Overall, most patients demonstrated stable disease with prolonged PFS; however, prominent target lesion progression occurred in some patients. Thus, PFS may capture VEGFR-TKI efficacy better than the objective response rate.
참고문헌 (14)
- Laurie SA, "Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands : a systematic review", Lancet Oncol, 12, pp.815~824 (2011)
- Sung MW, "Clinicopathologic predictors and impact of distant metastasis from adenoid cystic carcinoma of the head and neck", Arch Otolaryngol Head Neck Surg, 129, pp.1193~1197 (2003)
- Park S, "VEGF and Ki-67 overexpression in predicting poor overall survival in adenoid cystic carcinoma", Cancer Res Treat, 48, pp.518~526 (2016)
- Tchekmedyian V, "Phase II study of lenvatinib in patients with progressive, recurrent or metastatic adenoid cystic carcinoma", J Clin Oncol, 37, pp.1529~1537 (2019)
- Chau NG, "A phase II study of sunitinib in recurrent and", or metastatic adenoid cystic carcinoma(ACC)of the salivary glands : current progress and challenges in evaluating molecularly targeted agents in ACC, 2012, pp.23, 1562~1570
- Thomson DJ, "Phase II trial of sorafenib in advanced salivary adenoid cystic carcinoma of the head and neck", Head Neck, 37, pp.182~187 (2015)
- Kim Y, "Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck : a multicenter phase 2 study(Korean Cancer Study Group HN14-01)", Cancer, 123, pp.1958~1964 (2017)
- Keam B, "Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma", Cancer, 121, pp.2612~2617 (2015)
- Ho AL, "A phase II study of axitinib(AG-013736)in patients with incurable adenoid cystic carcinoma", Ann Oncol, 27, pp.1902~1908 (2016)
- Ho AL, "Phase II study of regorafenib in progressive, recurrent", metastatic adenoid cystic carcinoma, 2016, pp.34(15 Suppl), 6096~
- Hanna GJ, "A phase II trial of rivoceranib, an oral vascular endothelial growth factor receptor 2 inhibitor, for recurrent or metastatic adenoid cystic carcinoma", Clin Cancer Res, 29, pp.4555~4563 (2023)
- Kang EJ, "Randomized phase II study of axitinib versus observation in patients with recurred or metastatic adenoid cystic carcinoma", Clin Cancer Res, 27, pp.5272~5279 (2021)
- Jang S, "Clinical outcomes and prognostic factors of adenoid cystic carcinoma of the head and neck", Anticancer Res, 37, pp.3045~3052 (2017)
- van der Wal JE, "Distant metastases of adenoid cystic carcinoma of the salivary glands and the value of diagnostic examinations during follow-up", Head Neck, 24, pp.779~783 (2002)